Results per Page:
Decisions, decisions: factors that impact HCT outcomes in AML
From the Walter Group, Translational Sciences and Therapeutics Division
New tools in the pipeline for treating immune cell disorders
From the Walter Lab, Translational Sciences & Therapeutics Division
Location, location, location: where is key for CAR T-cell therapy
From the Walter lab, Translational Science and Therapeutics Division
Blood cancer experts Drs. Roland Walter and Mazyar Shadman receive endowed chairs
Chairs recognize innovation and contributions to blood cancer research
Eight Fred Hutch teams win Evergreen Fund awards
Research projects with commercial partnership potential receive grants of up to $200K
Keep your enemies closer: targeting membrane-proximal domains for improved immunotherapy
From the Walter Lab, Clinical Research Division
$3.5M grant to develop safer treatment for inherited blood disorders
Scientists will study radioactive particles that can precisely deliver a potent punch
Gimme shelter: CRISPR hides healthy cells from leukemia drug
In mouse study, gene-edited cells stay safe as immunotherapy attacks cancer
A FynomAb-ulous potential treatment for acute myeloid leukemia
From the Walter lab, Clinical Research Division
Cancer cells BiTE the dust through SMITE-bispecific mediated T cell activation
- from the Walter's and Mehlin's labs, Clinical Research Division
Good News at Fred Hutch
Dr. Roland Walter receives two grant awards for acute leukemia research; Dr. Jonathan Bricker to keynote behavioral therapy conference; Dr. Benjamin Anderson chairs NCCN committee that publishes clinical-practice guidelines for cervical cancer